{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T01:52:29Z","timestamp":1790301149408,"version":"4.1.0"},"reference-count":16,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2007,7,1]],"date-time":"2007-07-01T00:00:00Z","timestamp":1183248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2007,7]]},"DOI":"10.1016\/j.jns.2007.03.013","type":"journal-article","created":{"date-parts":[[2007,4,30]],"date-time":"2007-04-30T10:49:32Z","timestamp":1177930172000},"page":"137-143","source":"Crossref","is-referenced-by-count":79,"title":["Subcutaneous apomorphine in patients with advanced Parkinson's disease: A dose-escalation study with randomized, double-blind, placebo-controlled crossover evaluation of a single dose"],"prefix":"10.1016","volume":"258","author":[{"given":"Rajesh","family":"Pahwa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William C.","family":"Koller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard M.","family":"Trosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James H.","family":"Sherry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2007.03.013_bib1","doi-asserted-by":"crossref","first-page":"687","DOI":"10.2165\/00002512-200421110-00001","article-title":"Subcutaneous apomorphine. An evidence-based review of its use in Parkinson's disease","volume":"21","author":"Deleu","year":"2004","journal-title":"Drugs Aging"},{"key":"10.1016\/j.jns.2007.03.013_bib2","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/mds.1090","article-title":"Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature","volume":"16","author":"Ahlskog","year":"2001","journal-title":"Mov Disord"},{"key":"10.1016\/j.jns.2007.03.013_bib3","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2165\/00023210-200317070-00002","article-title":"Levodopa-induced response fluctuations in patients with Parkinson's disease: strategies for management","volume":"17","author":"van Laar","year":"2003","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jns.2007.03.013_bib4","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/978-3-7091-6360-3_11","article-title":"Current management of motor fluctuations in patients with advanced Parkinson's disease treated chronically with levodopa","volume":"56","author":"Melamed","year":"1999","journal-title":"J Neural Transm Suppl"},{"issue":"Suppl 2","key":"10.1016\/j.jns.2007.03.013_bib5","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1016\/S1353-8020(03)00021-X","article-title":"Prevention and treatment of motor fluctuations","volume":"9","author":"Stocchi","year":"2003","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.jns.2007.03.013_bib6","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1001\/archneur.58.9.1385","article-title":"A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for Parkinsonian off-state events","volume":"58","author":"Dewey","year":"2001","journal-title":"Arch Neurol"},{"issue":"Suppl 4","key":"10.1016\/j.jns.2007.03.013_bib7","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1212\/WNL.62.6_suppl_4.S12","article-title":"Intermittent subcutaneous apomorphine therapy in Parkinson's disease","volume":"62","author":"Factor","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2007.03.013_bib8","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1136\/jnnp.58.6.681","article-title":"Pen injected apomorphine against off phenomena in late Parkinson's disease: a double blind, placebo controlled study","volume":"58","author":"Ostergaard","year":"1995","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jns.2007.03.013_bib9","unstructured":"Data on file, Vernalis Pharmaceuticals Inc., February 2003 (APO301)."},{"key":"10.1016\/j.jns.2007.03.013_bib10","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1212\/WNL.17.5.427","article-title":"Parkinsonism: onset, progression and mortality","volume":"17","author":"Hoehn","year":"1967","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2007.03.013_bib11","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/mds.870090112","article-title":"Unified Parkinson's Disease Rating Scale characteristics and structure","volume":"9","author":"Martinez-Martin","year":"1994","journal-title":"Mov Disord"},{"key":"10.1016\/j.jns.2007.03.013_bib12","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/mds.870120425","article-title":"Correlation between results of motor section of UPDRS and Webster Scale","volume":"12","author":"Nouzeilles","year":"1997","journal-title":"Mov Disord"},{"issue":"Suppl 1","key":"10.1016\/j.jns.2007.03.013_bib13","first-page":"A81","article-title":"Continued efficacy and safety of subcutaneous injections of apomorphine in the treatment of off episodes in patients with Parkinson's disease","volume":"60","author":"Sherry","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2007.03.013_bib14","unstructured":"APOKYN\u2122 (apomorphine hydrochloride injection). US Prescribing Information. Research Triangle Park, NC, USA. Mylan Bertek Pharmaceuticals Inc; 2004."},{"key":"10.1016\/j.jns.2007.03.013_bib15","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1136\/jnnp.63.5.584","article-title":"Prevalence of orthostatic hypotension in Parkinson's disease","volume":"63","author":"Senard","year":"1997","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jns.2007.03.013_bib16","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1001\/archneur.57.10.1461","article-title":"Acute orthostatic hypotension when starting dopamine agonists in Parkinson's disease","volume":"57","author":"Kujawa","year":"2000","journal-title":"Arch Neurol"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X07002158?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X07002158?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,7]],"date-time":"2019-01-07T18:20:34Z","timestamp":1546885234000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X07002158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7]]},"references-count":16,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2007,7]]}},"alternative-id":["S0022510X07002158"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2007.03.013","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2007,7]]}}}